We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
Stockal+Disclaimer.pdf
1 own
1 watching
Current Price
$7.33
$-0.11
(-1.48%)
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
97.88M
52-Week High
13.93
52-Week Low
4.62
Average Volume
0.01M
Dividend Yield
--
P/E Ratio
--
Market Capitalization97.88M
52-Week High13.93
52-Week Low4.62
Average Volume0.01M
Dividend Yield--
P/E Ratio--
What does the Stockal+Disclaimer.pdf do?
Portage Biotech Inc., together with its subsidiaries, researches and develops pharmaceutical and biotechnology products. The company s product includes IMM60, an iNKT cell activator; IMM65, a PLGA-nanoparticle combined with a NY-ESO-1 peptide vaccine; INT230-6 that is in Phase I/II clinical trials for the treatment of solid tumors; STING, a small molecule that binds to the stimulator of interferon genes in cancer; CellPorter, a cell permeable peptide platform technology derived from human proteins; PPL-003, an ophthalmic solution; and SBI-101, a blood-conditioning technology to restore balance to the immune system after acute vital organ injury, such as acute kidney injury. It also focuses on nanolipogel technology for use in immune-oncology; and antibodies against a novel T-cell for use as a monotherapy and combination therapy for solid and haematological malignancies. In addition, the company develops antibodies implicated in the inflammatory tumor and tumor-infiltrating immune cell microenvironments; and FOXO4-P53 modulator and C-RAF inhibitor. Portage Biotech Inc. is based in Tortola, British Virgin Islands.
Read More
News & Events about Stockal+Disclaimer.pdf.
Globe Newswire
23days ago
Updated data support the proof of concept of using an iNKT agonist monotherapy (PORT-2) to induce immune response for patients with refractory NSCLC and melanomaWESTPORT, Conn., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company developing...
Globe Newswire
25days ago
Study will evaluate PORT-2 in combination with KEYTRUDA (pembrolizumab) for the treatment of patients with front-line as well as refractory non-small cell lung cancer (NSCLC)WESTPORT, Conn., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Portage Biotech Inc., (NASDAQ: PRTG) (Portage or the Company), a clinical-...
Globe Newswire
3 months ago
--Robust Pipeline Now Includes Five Clinical-Stage Small Molecule Immuno-Oncology Assets, Including Invariant Natural Killer T Cell (iNKT) Agonists and Adenosine Antagonists-- ---Cash Runway for New and Current Programs Potentially Extended into 2024-- WESTPORT, Conn., Aug. 29, 2022 (GLOBE NEWSWIRE...
Globe Newswire
4 months ago
--Company Continues to Execute on Core Business Model While Enhancing Value Proposition and Pipeline with Recent Transactions-- --Robust Pipeline Now Includes Four Fully Owned, Clinical-Stage Assets-- --Cash Runway for New and Current Programs Potentially Extended into 2024-- WESTPORT, Conn., Aug. ...
Globe Newswire
4 months ago
Portage now holds 100% ownership of iOx Therapeutics Ltd., buying out remainder of equity in exchange for PRTG stockWESTPORT, Conn., July 20, 2022 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company developing therapies to improve patient lives and ...
Frequently Asked Questions
Frequently Asked Questions
What is Stockal+Disclaimer.pdf share price today?
plus_minus_icon
Can Indians buy Stockal+Disclaimer.pdf shares?
plus_minus_icon
How can I buy Stockal+Disclaimer.pdf shares from India?
plus_minus_icon
Can Fractional shares of Stockal+Disclaimer.pdf be purchased?
plus_minus_icon
What are the documents required to start investing in Stockal+Disclaimer.pdf stocks?
plus_minus_icon
What is today’s traded volume of Stockal+Disclaimer.pdf?
plus_minus_icon
What is today’s market capitalisation of Stockal+Disclaimer.pdf?
plus_minus_icon
What is the 52-Week High and Low Range of Stockal+Disclaimer.pdf?
plus_minus_icon
What percentage is Stockal+Disclaimer.pdf down from its 52-Week High?
plus_minus_icon
What percentage is Stockal+Disclaimer.pdf up from its 52-Week Low?
plus_minus_icon
Current Price
$7.33
$-0.11
(-1.48%)
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00